



(12) Translation of
European patent specification

(11) NO/EP 3461821 B1

NORWAY

(19) NO

(51) Int Cl.

C07D 403/12 (2006.01) *C07D 403/04 (2006.01)*
A61K 31/4045 (2006.01) *C07D 403/10 (2006.01)*
A61P 29/00 (2006.01) *C07D 413/04 (2006.01)*
A61P 37/00 (2006.01) *C07D 417/04 (2006.01)*
C07D 209/18 (2006.01) *C07D 471/04 (2006.01)*
C07D 401/04 (2006.01) *C07D 487/04 (2006.01)*
C07D 401/06 (2006.01) *C07D 487/10 (2006.01)*
C07D 401/12 (2006.01)

Norwegian Industrial Property Office

- (45) Translation Published 2020.10.05
- (80) Date of The European
Patent Office Publication of
the Granted Patent 2020.05.13
- (86) European Application Nr. 18205411.4
- (86) European Filing Date 2015.10.23
- (87) The European Application's
Publication Date 2019.04.03
- (30) Priority 2014.10.24, US, 201462068225 P
- (84) Designated Contracting
States: AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ;
IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ;
SK ; SM ; TR
- Designated Extension
States: BA ; ME
- (62) Divided application EP3209656, 2015.10.23
- (73) Proprietor Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, NJ
08543, USA
- (72) Inventor AHMAD, Saleem, Bristol-Myers Squibb CompanyRoute 206 and Province Line Road,
Princeton, NJ 08543, USA
TEBBEN, Andrew J, Bristol-Myers Squibb CompanyRoute 206 and Province Line Road,
Princeton, NJ 08543, USA
GONG, Hua, Bristol-Myers Squibb CompanyRoute 206 and Province Line Road, Princeton, NJ
08543, USA
LIU, Qingjie, Bristol-Myers Squibb CompanyRoute 206 and Province Line Road, Princeton, NJ
08543, USA
NGU, Khehyong, Bristol-Myers Squibb CompanyRoute 206 and Province Line Road,
Princeton, NJ 08543, USA
WATTERSON, Scott Hunter, Bristol-Myers Squibb CompanyRoute 206 and Province Line
Road, Princeton, NJ 08543, USA
- (74) Agent or Attorney TANDBERG INNOVATION AS, Postboks 1570 Vika, 0118 OSLO, Norge

(54) Title **INDOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS**


(56) References

Cited: WO-A1-2008/144253, WO-A1-2013/157022, WO-A1-2014/210255

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. En forbindelse med formel (I):




5

eller et salt derav, hvor:


X er CR₄;

A er:



10

eller



15

Q₂ er -C(O)CH=CH₂, -C(O)CH=CHCH₂N(CH₃)₂, -C(O)C≡CR₇, -C(O)C≡C(C₁₋₃ hydroksyalkyl), -C(O)C≡C(fenyl), -C(O)C≡CSi(CH₃)₃, eller S(O)₂CH=CH₂;

20

R₁ er H, -CH₃, -CF₃, eller fenyl substituert med null eller 1 R₁₂;

R₂ er H, -CH₃, syklopropyl eller fenyl substituert med null eller 1 R₁₂, forutsatt at minst en av R₁ og R₂ er -CH₃;

R₃ er F eller Cl;

R₄ er H eller F;

R₆ er H, F, Cl, -CF₃, eller C₁₋₃ alkoksy;

R₇, ved hver forekomst, er uafhængig H, C₁₋₄ alkyl eller syklepropyl; og

R₁₂ er F, Cl, -CN, -CF₃, eller C₁₋₃ alkoksy.


5 2. Forbindelse ifølge krav 1 eller et salt derav, hvor:

R₆ er H eller F;

og

Q₂ er -C(O)CH=CH₂, -S(O)₂CH=CH₂, -C(O)CH=CHCH₂N(CH₃)₂, -C(O)C≡CH, -
 C(O)C≡CCH₃, -C(O)C≡CCH₂CH₃, -C(O)C≡CCH₂CH₂CH₃, -C(O)C≡C(CH₃)₂OH, -
 10 C(O)C≡CSi(CH₃)₃, -C(O)C≡C(syklepropyl), eller -C(O)C≡C(fenyl).

3. Forbindelse ifølge krav 1 som har strukturen:



15

4. Forbindelse ifølge krav 1 eller et salt derav, hvor forbindelsen er valgt fra: (RS)-4-(2-
 akryloyl-1,2,3,4-tetrahydroisokinolin-5-yl)-5-fluor-2,3-dimetyl-1H-indol-7-karboksamid

(95); 4-(1-akryloyl-1,2,3,4-tetrahydrokinolin-6-yl)-5-fluor-2,3-dimetyl-1H-indol-7-

karboksamid (97); 4-(1-akryloyl-1,2,3,4-tetrahydrokinolin-7-yl)-5-fluor-2,3-dimetyl-1H-

20 indol-7-karboksamid (99); (RS)-4-(4-akryloyl-3,4-dihydro-2-H-benzo[b][1,4]oksazin-8-

yl)-5-fluor-2,3-dimetyl-1H-indol-7-karboksamid (102); 4-(2-(but-2-ynoyl)-1,2,3,4-

tetrahydroisokinolin-5-yl)-5-fluor-2,3-dimetyl-1H-indol-7-karboksamid (129); 4-(2-

akryloyl-1,2,3,4-tetrahydroisokinolin-7-yl)-5-fluor-2,3-dimetyl-1H-indol-7-karboksamid

(131); 4-(2-(but-2-ynoyl)-1,2,3,4-tetrahydroisokinolin-7-yl)-5-fluor-2,3-dimetyl-1H-

25 indol-7-karboksamid (134); 4-(2-akryloyl-1,2,3,4-tetrahydroisokinolin-5-yl)-5-fluor-2,3-

dimetyl-1H-indol-7-karboksamid, enkle enantiomerer (153 og 154); 4-(4-akryloyl-3,4-

dihydro-2-Hbenzo[b][1,4]oksazin-8-yl)-5-fluor-2,3-dimetyl-1H-indol-7-karboksamid,
 enkle enantiomerer (155 og 156); 4-(2-akryloyl-4-fluor-1,2,3,4-tetrahydroisokinolin-5-

30 yl)-5-fluor-2,3-dimetyl-1H-indol-7-karboksamid, enkelt diastereomerer (169 til 172);

(RS)-4-(5-akryloyl-2,3,4,5-tetrahydrobenzo[b][1,4]oksazepin-9-yl)-5-fluor-2,3-dimetyl-

1H-indol-7-karboksamid (186); 4-(5-akryloyl-2,3,4,5-tetrahydrobenzo[b][1,4]oksazepin-

9-yl)-5-fluor-2,3-dimetyl-1H-indol-7-karboksamid, enkle enantiomerer (187 og 188);

(RS)-4-(2-akryloyl-7-fluor-1,2,3,4-tetrahydroisokinolin-5-yl)-5-fluor-2,3-dimetyl-1H-

indol-7-karboksamid (189); 4-(2-akryloyl-7-fluor-1,2,3,4-tetrahydroisokinolin-5-yl)-5-

fluor-2,3-dimetyl-1*H*-indol-7-karboksamid, enkle enantiomerer (190 og 191); 4-(2-akryloyl-1,2,3,4-tetrahydroisoquinolin-6-yl)-5-fluor-2,3-dimetyl-1*H*-indol-7-karboksamid (192); (*RS*)-4-(4-akryloyl-3,4-dihydro-2-*H*benzo[*b*][1,4]tiazin-8-yl)-5-fluor-2,3-dimetyl-1*H*-indol-7-karboksamid (194); 4-(4-akryloyl-3,4-dihydro-2-*H*benzo[*b*][1,4]tiazin-8-yl)-5-
5 fluor-2,3-dimetyl-1*H*-indol-7-karboksamid, enkle enantiomerer (195 og 196); (*RS*)-4-(2-akryloyl-1,2,3,4-tetrahydroisokinolin-5-yl)-5-fluor-3-metyl-2-(trifluormetyl)-1*H*-indol-7-karboksamid (197); 4-(2-akryloyl-1,2,3,4-tetrahydroisokinolin-5-yl)-5-fluor-3-metyl-2-(trifluormetyl)-1*H*-indol-7-karboksamid, enkle enantiomerer (198 og 199); 4-(2-(but-2-ynoyl)-1,2,3,4-tetrahydroisokinolin-6-yl)-5-fluor-2,3-dimetyl-1*H*-indol-7-karboksamid
10 (203); (*RS*)-4-(2-akryloyl-1,2,3,4-tetrahydroisokinolin-8-yl)-5-fluor-2,3-dimetyl-1-*H*-indol-7-karboksamid (204); 4-(2-akryloyl-1,2,3,4-tetrahydroisokinolin-8-yl)-5-fluor-2,3-dimetyl-1*H*-indol-7-karboksamid, enkle enantiomerer (205 og 206); (*RS*)-4-(2-akryloyl-1,2,3,4-tetrahydroisokinolin-5-yl)-3-syklopropyl-5-fluor-2-metyl-1-*H*-indol-7-karboksamid (209); 4-(2-akryloyl-1,2,3,4-tetrahydroisokinolin-5-yl)-3-syklopropyl-5-fluor-2-metyl-1-
15 *H*-indol-7-karboksamid, enkle enantiomerer (210 og 211); (*RS*)-4-(2-akryloyl-1,2,3,4-tetrahydroisokinolin-5-yl)-5-fluor-3-(4-fluorfenyl)-2-metyl-1-*H*-indol-7-karboksamid (212); 4-(2-akryloyl-1,2,3,4-tetrahydroisokinolin-5-yl)-5-fluor-3-(4-fluorfenyl)-2-metyl-1-*H*-indol-7-karboksamid, enkle enantiomerer (213 og 214); (*RS*)-4-(2-akryloyl-1,2,3,4-tetrahydroisokinolin-5-yl)-5-fluor-2-(4-fluorfenyl)-3-metyl-1-*H*-indol-7-karboksamid
20 (215); 4-(2-akryloyl-1,2,3,4-tetrahydroisokinolin-5-yl)-5-klor-2,3-dimetyl-1 *H*-indol-7-karboksamid (239); 4-(2-akryloyl-1,2,3,4-tetrahydroisokinolin-5-yl)-5-klor-2,3-dimetyl-1 *H*-indol-7-karboksamid, enkelt atropisomerer (240 og 264); og 4-(2-(but-2-ynoyl)-1,2,3,4-tetrahydroisokinolin-5-yl)-5-klor-2,3-dimetyl-1 *H*-indol-7-karboksamid (265).

25 5. Farmasøytisk sammensetning som omfatter en forbindelse ifølge et hvilket som helst av kravene 1-4 eller et farmasøytisk akseptabelt salt derav; og en farmasøytisk akseptabel bærer.

30 6. Forbindelse ifølge et hvilket som helst av kravene 1-4 eller et farmasøytisk akseptabelt salt derav, for anvendelse i terapi i behandling av autoimmun sykdom eller kronisk inflammatorisk sykdom.

35 7. Forbindelse eller farmasøytisk akseptabelt salt derav for anvendelse ifølge krav 6, hvor nevnte autoimmun sykdom eller kronisk inflammatorisk sykdom er valgt fra systemisk lupus erytematose (SLE), revmatoid artritt, multipel sklerose (MS) og Sjögrens syndrom.

8. Forbindelse ifølge et hvilket som helst av kravene 1-4, eller et salt derav, for anvendelse i terapi.